Stevanato Group releases transcript of Half Year 2026 Financial Results conference call - STVN News | Rallies
Stevanato Group releases transcript of Half Year 2026 Financial Results conference call S STVN • 2026-08-06 Q2 revenue and profitability
Q2 revenue rose 8% to €302 million.
Adjusted EBITDA increased to €78.7 million with a 26% margin.
Diluted EPS was €0.08 due to €12.2 million divestiture costs.
Product and regional performance
The Alina variable-dose pen won regulatory clearance in several European countries for liraglutide.
North America validations are expected in H2.
Biologics revenue grew 6%.
Divestiture and updated 2026 outlook
The company completed the sale of Balda C. Brewer; the unit had been expected to generate about €30 million revenue in 2026.
Guidance assumes a €15 million revenue reduction.
Updated 2026 outlook:
Revenue: €1.26 billion-€1.28 billion
Adjusted EBITDA: €335 million-€345.2 million
Adjusted diluted EPS: €0.60-€0.62
Free cash flow: breakeven to €20 million
Transcript of Half Year 2026 Financial Results conference call released
Stevanato Group released a transcript of its Half Year 2026 Financial Results Conference Call attended by the CEO, CFO, and Chief Communication and IR Officer.
XLRE
•
2026-08-06
STVN•
